COST-EFFECTIVENESS ANALYSIS OF DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

被引：0
|
作者：
Mantovani, L. G. [1 ]
Furneri, G. [2 ]
Cortesi, P. A. [1 ]
Puma, E. [3 ]
Santoni, L. [3 ]
Prosperini, L. [4 ]
机构：
[1] Univ Milano Bicocca, Milan, Italy
[2] EBMA Consulting SRL, Melegnano, Italy
[3] Biogen, Milan, Italy
[4] S Camillo Forlanini Hosp, Rome, Italy
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND24
引用
收藏
页码：S740 / S741
页数：2
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF TERIFLUNOMIDE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN GREECE
    Gourzoulidis, G.
    Kourlaba, G.
    Andreadou, E.
    Karageorgiou, K.
    Maniadakis, N.
    VALUE IN HEALTH, 2018, 21 : S339 - S339
  • [22] Dimethyl fumarate versus interferon for treatment of relapsing-remitting multiple Sclerosis
    Sattarnezhad, Neda
    Healy, Brian C.
    Baharnoori, Moogeh
    Diaz-Cruz, Camilo
    Stankiewicz, James
    Weiner, Howard L.
    Chitnis, Tanuja
    NEUROLOGY, 2017, 88
  • [23] Successful treatment with dimethyl fumarate in a child with relapsing-remitting multiple sclerosis
    Saijo, Naoya
    Abe, Yu
    Oikawa, Yoshitsugu
    Okubo, Yukimune
    Endo, Wakaba
    Numata-Uematsu, Yurika
    Takahashi, Toshiyuki
    Uematsu, Mitsugu
    BRAIN & DEVELOPMENT, 2022, 44 (05): : 353 - 356
  • [24] Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis
    Muller, Jannis
    Schadelin, Sabine
    Lorscheider, Johannes
    Benkert, Pascal
    Hanni, Peter
    Schmid, Jurg
    Kuhle, Jens
    Derfuss, Tobias
    Granziera, Cristina
    Yaldizli, Ozgur
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (12) : 3809 - 3818
  • [25] Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis
    Lorscheider, Johannes
    Benkert, Pascal
    Lienert, Carmen
    Haenni, Peter
    Derfuss, Tobias
    Kuhle, Jens
    Kappos, Ludwig
    Yaldizli, Oezguer
    JOURNAL OF NEUROLOGY, 2021, 268 (03) : 941 - 949
  • [26] COST-EFFECTIVENESS OF FINGOLIMOD, TERIFLUNOMIDE, DIMETHYL FUMARATE AND INTRAMUSCULAR INTERFERON BETA-1A IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Zhang, X.
    Hay, J. W.
    VALUE IN HEALTH, 2014, 17 (03) : A59 - A60
  • [27] Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis
    Mueller, J.
    Schaedelin, S.
    Benkert, P.
    Haenni, P.
    Schmid, J.
    Derfuss, T.
    Kuhle, J.
    Yaldizli, O.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 676 - 676
  • [28] COST-EFFECTIVENESS ANALYSIS OF DACLIZUMAB BETA IN THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS IN ITALY
    Demma, R.
    Casamassima, G.
    Cocco, E.
    Di Turi, R.
    Paolicelli, D.
    Fantaccini, S.
    Santoni, L.
    Fumeri, G.
    VALUE IN HEALTH, 2017, 20 (09) : A723 - A723
  • [29] THE COST-EFFECTIVENESS OF DISEASE MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Bozkaya, D.
    Livingston, T. P.
    Migliaccio-Walle, K.
    Mehta, S.
    Odom, T.
    VALUE IN HEALTH, 2015, 18 (03) : S283 - S283
  • [30] The Effectiveness of Dimethyl Fumarate Monotherapy in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis
    Kawalec, Pawel
    Mikrut, Alicja
    Wisniewska, Natalia
    Pilc, Andrzej
    CURRENT NEUROPHARMACOLOGY, 2014, 12 (03) : 256 - 268
12345